Polyuria Following Supraventricular Arrhythmia
Yes, polyuria occurring immediately after a rapid heart rate episode is a reliable clinical indicator of sustained supraventricular arrhythmia, caused by the release of atrial natriuretic peptide (ANP) in response to increased atrial pressures during atrial contraction against a closed atrioventricular valve.
Pathophysiologic Mechanism
The mechanism underlying post-arrhythmia polyuria is well-established through multiple lines of evidence:
ANP levels increase dramatically during supraventricular tachycardia (SVT), rising from baseline levels of approximately 117 pg/ml to 251 pg/ml during induced episodes 1. This represents more than a doubling of circulating ANP concentrations.
The trigger is increased atrial pressure, which rises significantly during SVT (from 4.3 mm Hg at baseline to 7.4 mm Hg during tachycardia), with a modest but significant linear correlation (r = 0.60) between changes in plasma ANP and right atrial pressure 1.
ANP surges faster than other natriuretic peptides during SVT episodes. While ANP levels rise steeply after 30 minutes of paroxysmal SVT and then rapidly decline after termination, BNP and CNP increase less sharply and continue to rise even after tachycardia termination 2. This differential response pattern makes ANP the primary mediator of acute polyuria.
Clinical Presentation and Timing
The polyuria associated with SVT has characteristic features:
Polyuria occurs in approximately 50% of patients experiencing paroxysmal supraventricular tachyarrhythmias 3. This symptom is more frequent in younger patients with shorter duration of tachycardia.
Patients with polyuria have significantly higher ANP concentrations compared to those without polyuria during acute attacks 3. In one study, 22 of 23 patients with paroxysmal SVT and all 7 patients with atrial flutter had elevated ANP levels 4.
The polyuria includes both increased urine volume and natriuresis, with urine volume increasing to 580% of control and urinary sodium excretion to 278% of control in affected patients 5.
Dual Hormonal Mechanism
The polyuria is not solely due to ANP release but involves a coordinated hormonal response:
Arginine vasopressin (AVP) is simultaneously suppressed during SVT, with plasma AVP concentrations decreasing during tachycardia and rebounding above control levels in the post-SVT period 5.
Both ANP stimulation and AVP inhibition are elicited by increased atrial pressure, working synergistically to produce polyuria with increased free water clearance and natriuresis 6.
Diagnostic Utility
This physiologic response has practical clinical implications:
Post-episode polyuria serves as a clinical clue to distinguish sustained supraventricular arrhythmias from other causes of tachycardia 1, 4. The presence of polyuria after a rapid heart rate episode supports the diagnosis of SVT rather than sinus tachycardia or other non-arrhythmic causes.
The rapid normalization of ANP after termination (within 30 minutes) correlates with resolution of symptoms 4, 2, providing a temporal relationship that strengthens the diagnostic association.
Important Caveats
Several clinical considerations warrant attention:
Not all patients with SVT experience polyuria, as only 50% report this symptom 3. The absence of polyuria does not exclude sustained SVT.
The highest ANP values do not always correlate with polyuria presence 3, suggesting individual variation in renal responsiveness to ANP or differences in AVP suppression.
Chronic atrial fibrillation shows different patterns, with elevated baseline ANP levels (138 pg/ml) that decrease after cardioversion to sinus rhythm (116 pg/ml) 1, indicating that chronic arrhythmias produce sustained but lower-level ANP elevation compared to acute paroxysmal episodes.